Helix BioPharma has completed the interim review of its ongoing Phase I/II study of L-DOS47 in Poland. The review was not a formal analysis of data, but a review of safety and clinical parameters collected during the study to date. Enrollment has completed for the first four dosing cohorts. Each cohort enrolled and dosed three patients. Dose levels were increased at each new cohort following a review of safety data from the previous cohort by the Trial Steering Committee. All 12 patients treat...